BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 7, 2026
Home
»
Newsletters
» BioWorld
BioWorld
March 9, 2006
View Archived Issues
In Huntington's, Are Inclusion Bodies Answer, Not Problem?
Read More
Neuromed's $25M To Fuel Calcium Channel Research
Read More
Alexza Prices IPO At $44M To Finance Clinical Work
Read More
Clinical Roundup
Read More
Other News To Note
Read More
FDA Committee Advocates Tysabri's Return To Market
GAITHERSBURG, Md. - Members of an FDA advisory committee voted unanimously in favor of bringing Tysabri (natalizumab) back to the multiple sclerosis market, but with restrictions. (BioWorld Today)
Read More
Neurocrine Dropping APL-MS Work After Missed Endpoint
Read More
